Scientific article
English

Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program

Published inPediatric research, vol. 64, no. 2, p. 200-204
Publication date2008
Abstract

The oral dual endothelin receptor antagonist bosentan has been shown to improve the short- and medium-term course of adult pulmonary arterial hypertension (PAH); however, data from clinical studies in children are limited. This analysis investigated the safety profile of bosentan in pediatric patients in a European, prospective, noninterventional, Internet-based postmarketing surveillance database (Tracleer PMS). Pediatric patients (aged 2-11 y) were compared with patients aged > or =12 y. Over a 30-mo period, 4994 patients, including 146 bosentan-naïve pediatric patients (51.4% males), were captured in the database. Predominant etiologies in children were idiopathic PAH (40.4%) and PAH related to congenital heart disease (45.2%). The majority of children were in New York Heart Association functional class II (28.1%) or III (50.7%), and median exposure to bosentan was 29.1 wk. Elevated aminotransferases were reported in 2.7% of children versus 7.8% of patients > or =12 y. The discontinuation rate was 14.4% in children versus 28.1% in patients > or =12 y. The Tracleer PMS results provide unique information on pediatric PAH in Europe. They also suggest that Tracleer may be better tolerated in children than in adults. This observation confirms the value of monthly monitoring of liver function for the duration of bosentan treatment.

Keywords
  • Antihypertensive Agents/adverse effects/therapeutic use
  • Child
  • Child, Preschool
  • Europe
  • Female
  • Humans
  • Hypertension, Pulmonary/drug therapy/metabolism
  • Liver
  • Longitudinal Studies
  • Male
  • Product Surveillance, Postmarketing
  • Sulfonamides/adverse effects/therapeutic use
  • Transaminases/metabolism
Citation (ISO format)
BEGHETTI, Maurice et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. In: Pediatric research, 2008, vol. 64, n° 2, p. 200–204. doi: 10.1203/PDR.0b013e318179954c
Main files (1)
Article (Accepted version)
accessLevelRestricted
Identifiers
ISSN of the journal0031-3998
549views
0downloads

Technical informations

Creation03/03/2009 11:31:00 AM
First validation03/03/2009 11:31:00 AM
Update time03/14/2023 3:02:54 PM
Status update03/14/2023 3:02:54 PM
Last indexation10/29/2024 11:18:19 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack